Taltz (ixekizumab) — Medica

Initial criteria

• age > 18 years
• prescribed by or in consultation with a rheumatologist or dermatologist

Reauthorization criteria

• therapy established for at least 6 months
• EITHER beneficial clinical response from baseline by objective measure (e.g., DAPSA, CPDAI, PsA DAS, Grace Index, LEI, SPARCC enthesitis score, Leeds Dactylitis Instrument Score, MDA, PsAID-12, or serum markers such as CRP or ESR) OR improvement in at least one symptom (e.g., less joint pain, morning stiffness, fatigue, improved function or ADLs, decreased soft tissue swelling)

Approval duration

initial 6 months, reauthorization 1 year